Anti-oestrogen-based therapies, often combined with a CDK4/6 inhibitor, are the current
standard-of-care first-line therapy for patients with advanced-stage hormone receptor …

The establishment and utilization of preclinical animal models constitute a pivotal aspect
across all facets of cancer research, indispensably contributing to the comprehension of …

Abstract Cyclin-dependent kinases (CDKs) 4 and 6 (CDK4/6) are important regulators of the
cell cycle. Selective CDK4/6 small-molecule inhibitors have shown clinical activity in …

Purpose of review Update on the most recent clinical evidence on CDK4/6 inhibitors
(CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth …

More than half of the~ 20,000 protein-encoding human genes have paralogs. Chemical
proteomics has uncovered many electrophile-sensitive cysteines that are exclusive to …

Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main
resistance mechanism to CDK4/6 inhibition in hormone-positive (HR+) breast cancer …

Nuclear receptors (NRs) regulate transcription in response to ligand binding and NR
modulation allows pharmacological control of gene expression. Although some NRs are …

CCNE1 amplification occurs in breast cancer and currently lacks effective therapies.
PKMYT1 as a synthetic lethal target for CCNE1 amplification holds promise for the treatment …

Drug resistance remains a major obstacle in cancer treatment, leading to treatment failures
and high mortality rates. Despite advancements in therapies, overcoming resistance …

The therapeutic landscape for hormone receptor-positive (HR+) breast carcinoma has
undergone a significant transformation with the advent of cyclin-dependent kinase (CDK) 4/6 …